Loading
Life sciences · Journal article
Current Oncology · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Multifocal and multicentric (MF/MC) breast cancers are associated with increased axillary lymph node involvement, but the relevance of the number of invasive tumor foci is less clear. This retrospective study included 1087 patients with non-metastatic invasive breast cancer who underwent definitive surgery between 2010 and 2022 without prior neoadjuvant therapy. Patients were grouped as having one, two, or three or more invasive foci; the three-or-more-foci category was used pragmatically to avoid small subgroups at higher focus counts rather than as a data-derived threshold. Multivariable logistic and Cox regression analyses were used to evaluate advanced nodal disease (N2/N3) and disease-free survival (DFS), respectively. N2/N3 disease was present in 18.4%, 19.0%, and 38.2% of patients, respectively (p < 0.001). Three or more foci were independently associated with N2/N3 disease (OR 2.81, 95% CI 1.65–4.79; p < 0.001), whereas two foci were not. At a median follow-up of 113.1 months, 10-year DFS rates were 77.0%, 82.5%, and 55.7%, respectively (log-rank p = 0.003). Three or more foci remained associated with poorer DFS after multivariable adjustment (HR 1.58, 95% CI 1.07–2.33; p = 0.022), whereas two foci were not. A statistically significant difference in OS was not demonstrated (log-rank p = 0.088), although the study may have had limited power for this endpoint. Greater nodal burden and poorer DFS were mainly observed in patients with three or more invasive foci. Focus number may help characterize this heterogeneity within MF/MC disease, although its value beyond total invasive tumor burden remains uncertain.